FDA approved Medtronic PLC’s CoreValve self-expanding transcatheter aortic valve implant (TAVI) system for patients with severe aortic stenosis patients who are too ill to withstand surgical valve replacement, the company announced Jan. 17.
The approval comes several months before either the company or analysts predicted. Medtronic announced in October that FDA would not...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?